Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 10.16B P/E 167.97 EPS this Y 85.00% Ern Qtrly Grth -31.90%
Income 339.2M Forward P/E 22.06 EPS next Y 52.70% 50D Avg Chg 8.00%
Sales 2.12B PEG 0.77 EPS past 5Y 10.87% 200D Avg Chg -1.00%
Dividend N/A Price/Book 5.49 EPS next 5Y 32.80% 52W High Chg -19.00%
Recommedations 1.80 Quick Ratio 3.78 Shares Outstanding 100.98M 52W Low Chg 17.00%
Insider Own 0.99% ROA 11.51% Shares Float 99.78M Beta 0.37
Inst Own 96.05% ROE 15.55% Shares Shorted/Prior 2.23M/2.29M Price 104.14
Gross Margin 68.55% Profit Margin 16.00% Avg. Volume 785,827 Target Price 167.92
Oper. Margin 25.06% Earnings Date Oct 29 Volume 1,179,265 Change 0.68%
About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Neurocrine Biosciences, Inc. News
11/12/24 High Growth Tech Stocks Featuring Three Prominent US Companies
11/08/24 Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality
11/07/24 Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
11/05/24 Neurocrine Biosciences to Participate at Investor Conferences in November
11/04/24 Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
11/04/24 Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
10/31/24 Neurocrine Biosciences Inc (NBIX) Q3 2024 Earnings Call Highlights: Strong Sales and Strategic ...
10/31/24 Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight
10/30/24 Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10/30/24 Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
10/30/24 Neurocrine: Q3 Earnings Snapshot
10/30/24 Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
10/23/24 Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
10/23/24 Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
10/16/24 Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds?
10/11/24 Exploring Three High Growth Tech Stocks in the United States
10/09/24 Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
10/03/24 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
09/30/24 Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
09/19/24 Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
NBIX Chatroom

User Image JFDI Posted - 18 hours ago

$NBIX island setting up.

User Image Kian_Gardner Posted - 20 hours ago

$RDY $NBIX LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image BabyBull92 Posted - 6 days ago

$NBIX seeing 148 volume on the $130 calls expiring tomorrow. Curious

User Image LauriceGeel Posted - 1 week ago

📈 Stock Performance for $NBIX over the Last Month: Opening Price: $115.13 Closing Price: $127.01 Highest Price: $131.26 Lowest Price: $113.88 Percentage Change: 10.32% 📊 Financial Summary: Revenue: 1,887,100,000 Net Income: 249,700,000 Total Assets: 3,251,400,000 Total Liabilities: 1,019,400,000 Operating Cash Flow: N/A Note: For a secret strategy and more detailed information, please visit the link in my bio. Thank you!

User Image GoIrish1776 Posted - 1 week ago

$NBIX AbbVie's $9B schizophrenia prospect flunks phase 2 trials https://www.fiercebiotech.com/biotech/abbvies-9b-schizophrenia-prospect-flunks-phase-2-trials-handing-advantage-bms

User Image RNASequencing Posted - 1 week ago

$NBIX nbix will also likely be red today

User Image Pika_Capital Posted - 1 week ago

$ABBV $CERE $8b down the drain lol 🤡 Should have bought $NBIX for $15-20B

User Image UncleStock Posted - 2 weeks ago

$EXEL $UTHR $CORT $NBIX suggested for $BTK US ARCA Biotechnology - value screen: https://zpr.io/tWJwE

User Image Thelonius_Stonk Posted - 2 weeks ago

$NBIX likely needs more time building out a base down here, but improving. adding back to watch

User Image WhisperNumber Posted - 2 weeks ago

$EXAS #earnings after close, the expectation from the WhisperNumber community is $0.17, 38c ahead of analyst estimates. Earnings came in $0.29 ahead of the whisper last quarter. 57% beat rate. Implied move +/-12.7%. https://www.whispernumber.com/wr_alerts.jsp #options #trading $PCVX $BMRN $NBIX

User Image ProfitValkyrie Posted - 2 weeks ago

🚨 MYNZ HUGE PR drop incoming before the Nov 13 meeting 🔥 Someone is pushing these dates of upcoming NEWS 3 biggest stock alert channels announced, might consider to add now, who knows. $RDY $NBIX

User Image 6k_investor Posted - 10/31/24

$CYCN the chair of the board of $CYCN - Errol De Souza, PhD, founded $NBIX Neurocrine Biosciences Inc (A $12 BILLION DOLLAR COMPANY) trading at $120 per share. We saw $MNPR run $4 to $40 OFF THE SAME TYPE OF PR we are expecting from $CYCN ( $DRUG ran from $1 to $80 with the same 2M share float. This one has no dilution AT ALL with a pending catalyst.

User Image 6k_investor Posted - 10/31/24

$CYCN is a tiny $7M Market Cap Penny Stock with $4.5M Cash that hasn’t diluted at all in the last year and has ZERO DILUTION Filings. ZERO DEBT. Trading with a TINY 2M share float. 👇*MUST SEE DD BELOW*👇 This company is ran by VERY high power executives with a very impressive track record. You won’t find another Biotech penny stock with an $8M valuation that has this kind of leadership. The new CEO (Regina Graul) appointed in August was the Vice President of $EQRx which got bought out for $950M. Peter Hecht, PhD - The current director / strategic advisor and EX CEO of $CYCN founded $IRWD (Currently a $654M Company) it was trading over a $3 Billion Dollar Valuation in 2018! (Peter was the CEO of $IRWD from 1998 to 2019) Another director of $CYCN - Errol De Souza, PhD, founded $NBIX Neurocrine Biosciences Inc (A $12 BILLION DOLLAR COMPANY) trading at $120 per share. Another director of the company - Michael Higgins served as Interm CEO of $VYGR currently a $368M company.

User Image joydivision Posted - 10/31/24

$NBIX How fast it was sold off at 130 was really bad - some heavy bags weighing down this one from past

User Image Idvst8 Posted - 10/30/24

$NBIX - Cheap here. GEM

User Image Stocksrunner Posted - 10/30/24

$NBIX This beauty just raised guidance after beating Q3 estimates. The momentum is building—will it find the strength to rise higher?

User Image JFDI Posted - 10/30/24

$NBIX love that monthly. weekly/daily not so much, but feels like opp here.

User Image OpenOutcrier Posted - 10/30/24

$NBIX (+8.0% pre) Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance https://ooc.bz/l/46228

User Image GoIrish1776 Posted - 10/30/24

$NBIX Share buyback is nice to see.

User Image Pika_Capital Posted - 10/30/24

$NBIX great quarter.

User Image AivelX Posted - 10/29/24

💡 #AivelX Premarket Earnings Insights (4/5) 🧵 Earnings breakdown for: NBIX, SHAK, TT, WING $NBIX - Ref.Earnings: 67 Gap Up Prob.: 45%, max 4.6%, min -11.2%, avg -0.8% Avg Low vs Open: -3.5% Avg Close vs Low: 1.8% Avg Low-High %: 5.1% 5 Days Later: 60% new highs, 73% new lows Earnings Day: 15% broke 120.2 (+3.3%) $SHAK - Ref.Earnings: 1951 Gap Up Prob.: 67%, max 21.9%, min -13.1%, avg 0.7% Avg Low vs Open: -1.3% Avg Close vs Low: 2.4% Avg Low-High %: 3.7% 5 Days Later: 74% new highs, 48% new lows Earnings Day: 42% broke 110.8 (-3%) $TT - Ref.Earnings: 204 Gap Up Prob.: 46%, max 6.9%, min -13.1%, avg -0.4% Avg Low vs Open: -3.2% Avg Close vs Low: 1.5% Avg Low-High %: 4.4% 5 Days Later: 61% new highs, 57% new lows Earnings Day: 25% broke 378 (-3.4%) $WING - Ref.Earnings: 141 Gap Up Prob.: 78%, max 14%, min -6.1%, avg 1.4% Avg Low vs Open: -1.2% Avg Close vs Low: 3.3% Avg Low-High %: 4.6% 5 Days Later: 88% new highs, 28% new lows Earnings Day: 11% broke 357 (-3.8%)

User Image GoIrish1776 Posted - 10/28/24

$NBIX What a colossal disappointment this stock and, frankly, the company has been over the past 7 years.

User Image UncleStock Posted - 10/27/24

$UTHR $EXEL $NBIX $CORT suggested for $BTK US ARCA Biotechnology - value screen: https://zpr.io/tWJwE

User Image joydivision Posted - 10/22/24

$NBIX Oppenheimer maintained outperform and target 192$. Ridiculous - we have new targets from 114$ to 192$ now

User Image joydivision Posted - 1 month ago

@dennismccain GAMCO is scooping it up and touting as a excellent opportunity. In the end I maybe will just slam Aerospace and Defence / Industrials and Tech ETF-s and find something else to do with that extra time instead of stock picking and avoiding surprising events like those what happened to $ELV or $NBIX recently:)

User Image GoIrish1776 Posted - 1 month ago

$NBIX Will 'Game Changer' Antipsychotic Live Up to the Hype? https://www.medscape.com/viewarticle/will-game-changer-antipsychotic-live-hype-2024a1000h5i

User Image UncleStock Posted - 1 month ago

$UTHR $EXEL $NBIX $CORT suggested for $BTK US ARCA Biotechnology - value screen: https://zpr.io/tWJwE

User Image joydivision Posted - 1 month ago

$NBIX StateStreet picked today up 5% aka 5 million shares according to today 13G Filing

User Image Quantumup Posted - 1 month ago

Piper Sandler reiterated $CRNX Overweight/$97, after co-hosting a CAH/Cushing's KOL call—in CAH the MD was impressed by initial P2 data (n=6)/expects cont'd success (add'l data YE24)—in Cushing's the KOL thinks atumelnant has 1L pot based on initial results (n=5; add'l data guided YE24): $nbix

User Image Doozio Posted - 1 month ago

$NBIX 3wt bahhhhhhhhtom of a base sitting right on its 40w as da 🧠 is about to spread thru ♾️

Analyst Ratings
Cantor Fitzgerald Overweight Sep 16, 24
Barclays Overweight Sep 9, 24
Cantor Fitzgerald Overweight Aug 29, 24
RBC Capital Sector Perform Aug 29, 24
HC Wainwright & Co. Buy Aug 29, 24
Needham Hold Aug 29, 24
Piper Sandler Overweight Aug 29, 24
BMO Capital Market Perform Aug 29, 24
Jefferies Buy Aug 19, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
ROBERTS EIRY Chief Medical Office.. Chief Medical Officer Jan 31 Sell 140.7906 1,457 205,132 20,832 02/02/24
Onyia Jude Chief Scientific Off.. Chief Scientific Officer Jan 31 Sell 141.94 126 17,884 11,843 02/02/24
Lippoldt Darin Chief Legal Officer Chief Legal Officer Jan 31 Sell 140.6478 1,250 175,810 37,005 02/02/24
GORMAN KEVIN CHARLES Chief Executive Offi.. Chief Executive Officer Jan 31 Sell 140.6888 2,707 380,845 502,188 02/02/24
Gano Kyle Chief Business Devel.. Chief Business Development Off Jan 31 Sell 140.696 1,541 216,813 131,635 02/02/24
Delaet Ingrid Chief Regulatory Off.. Chief Regulatory Officer Jan 31 Sell 140.86 1,045 147,199 6,865 02/02/24
Cooke Julie Chief Human Resource.. Chief Human Resources Officer Jan 31 Sell 141.32 1,740 245,897 17,263 02/02/24
Boyer David W. Chief Corp. Affairs.. Chief Corp. Affairs Officer Jan 31 Sell 140.8 2,096 295,117 4,894 02/02/24
BENEVICH ERIC Chief Commercial Off.. Chief Commercial Officer Jan 31 Sell 140.7844 1,207 169,927 37,601 02/02/24
ABERNETHY MATT Chief Financial Offi.. Chief Financial Officer Jan 31 Sell 140.7161 1,283 180,539 28,284 02/02/24
Lippoldt Darin Chief Legal Officer Chief Legal Officer Jan 22 Sell 139.86 10,000 1,398,600 35,882 01/24/24
Lippoldt Darin Chief Legal Officer Chief Legal Officer Jan 22 Option 79.02 10,000 790,200 45,882 01/24/24
GORMAN KEVIN CHARLES Chief Executive Offi.. Chief Executive Officer Jan 08 Sell 133.23 167,858 22,363,721 499,754 01/10/24
GORMAN KEVIN CHARLES Chief Executive Offi.. Chief Executive Officer Jan 08 Option 19.59 167,858 3,288,338 561,777 01/10/24
Gano Kyle Chief Business Devel.. Chief Business Development Off Jan 02 Sell 131.46 75,000 9,859,500 130,250 01/04/24
Gano Kyle Chief Business Devel.. Chief Business Development Off Jan 02 Option 19.59 75,000 1,469,250 136,366 01/04/24
RASTETTER WILLIAM H Director Director Jan 02 Sell 131.47 11,044 1,451,955 51,741 01/04/24
RASTETTER WILLIAM H Director Director Jan 02 Option 12.98 20,000 259,600 62,785 01/04/24
LYONS GARY A Director Director Dec 22 Sell 130.0443 10,000 1,300,443 193,697 12/27/23
Cooke Julie Chief Human Resource.. Chief Human Resources Officer Dec 22 Sell 128.39 24,000 3,081,360 17,263 12/27/23
Cooke Julie Chief Human Resource.. Chief Human Resources Officer Dec 22 Option 71.44 24,000 1,714,560 27,263 12/27/23
ROBERTS EIRY Chief Medical Office.. Chief Medical Officer Dec 12 Sell 120.3 13,925 1,675,178 29,521 12/14/23
ROBERTS EIRY Chief Medical Office.. Chief Medical Officer Dec 12 Option 81.05 13,925 1,128,621 36,468 12/14/23
ROBERTS EIRY Chief Medical Office.. Chief Medical Officer Dec 07 Sell 120.27 77,679 9,342,453 29,521 12/11/23
ROBERTS EIRY Chief Medical Office.. Chief Medical Officer Dec 07 Option 79.63 77,679 6,185,579 29,621 12/11/23
ROBERTS EIRY Chief Medical Office.. Chief Medical Officer Dec 06 Sell 120.03 8,396 1,007,772 29,521 12/08/23
ROBERTS EIRY Chief Medical Office.. Chief Medical Officer Dec 06 Option 77.81 8,396 653,293 37,917 12/08/23
Lippoldt Darin Chief Legal Officer Chief Legal Officer Dec 06 Sell 119.86 20,830 2,496,684 35,882 12/08/23
Lippoldt Darin Chief Legal Officer Chief Legal Officer Dec 06 Option 43.24 20,830 900,689 56,712 12/08/23
Onyia Jude Chief Scientific Off.. Chief Scientific Officer Nov 29 Sell 113.5705 2,331 264,733 11,732 12/01/23
Boyer David W. Chief Corp. Affairs.. Chief Corp. Affairs Officer Oct 02 Sell 112.68 1,437 161,921 4,894 10/04/23
LYONS GARY A Director Director Sep 12 Sell 115.02 5,000 575,100 203,697 09/14/23
LYONS GARY A Director Director Sep 12 Option 12.98 5,000 64,900 208,697 09/14/23
ROBERTS EIRY Chief Medical Office.. Chief Medical Officer Aug 21 Sell 107.3758 3,198 343,388 29,521 08/23/23
Onyia Jude Chief Scientific Off.. Chief Scientific Officer Aug 21 Sell 107.3696 3,198 343,368 9,638 08/23/23
Lippoldt Darin Chief Legal Officer Chief Legal Officer Aug 21 Sell 107.388 2,132 228,951 46,991 08/23/23
GORMAN KEVIN CHARLES Chief Executive Offi.. Chief Executive Officer Aug 21 Sell 107.3988 9,328 1,001,816 499,754 08/23/23
Gano Kyle Chief Business Devel.. Chief Business Development Off Aug 21 Sell 107.4075 2,132 228,993 130,250 08/23/23
Delaet Ingrid Chief Regulatory Off.. Chief Regulatory Officer Aug 21 Sell 107.4219 1,404 150,820 4,645 08/23/23
Cooke Julie Chief Human Resource.. Chief Human Resources Officer Aug 21 Sell 107.4065 2,132 228,991 18,087 08/23/23
Boyer David W. Chief Corp. Affairs.. Chief Corp. Affairs Officer Aug 21 Sell 107.4138 1,600 171,862 6,193 08/23/23
BENEVICH ERIC Chief Commercial Off.. Chief Commercial Officer Aug 21 Sell 107.3975 1,600 171,836 36,436 08/23/23
ABERNETHY MATT Chief Financial Offi.. Chief Financial Officer Aug 21 Sell 107.3914 2,132 228,958 27,131 08/23/23
RASTETTER WILLIAM H Director Director May 01 Sell 101.43 4,300 436,149 42,785 05/03/23
RASTETTER WILLIAM H Director Director May 01 Option 12.71 7,625 96,914 47,085 05/03/23
Cooke Julie Chief Human Resource.. Chief Human Resources Officer May 01 Sell 103.8913 11,397 1,184,049 16,169 05/03/23
ROBERTS EIRY Chief Medical Office.. Chief Medical Officer Apr 24 Sell 103.4763 14,400 1,490,059 26,644 04/26/23
RASTETTER WILLIAM H Director Director Apr 19 Sell 105.02 6,937 728,524 39,460 04/21/23
RASTETTER WILLIAM H Director Director Apr 19 Option 12.71 12,375 157,286 45,494 04/21/23
Cooke Julie Chief Human Resource.. Chief Human Resources Officer Feb 06 Sell 103.72 17,079 1,771,434 27,424 02/08/23